Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
Definitions of hypoxaemia, hypoxia, type 1 respiratory failure and hyperoxaemia Definition of hypercapnia and type 2 respiratory failure Definition of acidosis (respiratory acidosis and metabolic ...
In the ACACIA-HCM trial, aficamten demonstrated a statistically significant improvement over placebo in both KCCQ-CSS (P =.021) and pVO2 (P =.003) at 36 weeks, with no new safety signals observed.
Cytokinetics' cardiac myosin inhibitor Myqorzo has succeeded where first-to-market Camzyos from Bristol Myers Squibb failed, hitting the mark in a phase 3 trial in non-obstructive hypertrophic ...
Within the cardiac sarcomere, myosin in thick filaments interacts with actin in thin filaments to promote contraction. The chemomechanical cycle represents the steps leading to myosin powerstrokes ...
Stifel analysts said the label for cardiac myosin inhibitor Myqorzo is in line with their expectations and is differentiated compared with BMS’ Camzyos. Cytokinetics has won FDA approval of its ...
Company to Host Investor Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the ...
Sanja Jelic, MD, is board-certified in sleep medicine, critical care medicine, pulmonary disease, and internal medicine. A PaO2 test measures oxygen pressure in arterial blood to help guide treatment ...
At 1 year after participants’ ICU stay for acute respiratory failure, mean DLCO was about 5% lower in those who had an ICU oxygenation target of 60 vs 90 mm Hg. Cognitive impairment levels among ...
Cytokinetics, Incorporated's (CYTK) shares surged 40.4% on Sept. 2, driven by positive results from a phase III study on cardiovascular candidate aficamten. On Aug. 30, Cytokinetics presented primary ...
Data from the late-stage MAPLE-HCM study position Cytokinetics’ cardiac myosin inhibitor aficamten as a potential first-line therapy for patients with obstructive hypertrophic cardiomyopathy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results